Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis

Ebina, K.; Hirao, M.; Hashimoto, J.; Matsuoka, H.; Iwahashi, T.; Chijimatsu, R.; Etani, Y.; Okamura, G.; Miyama, A.; Yoshikawa, H.

doi:https://doi.org/10.1007/s00198-018-4492-y

Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis

Ebina, K.; Hirao, M.; Hashimoto, J. et al.

Osteoporosis International, 2018, 29(7), 1627-1636

Number of Access:1,220（2025-09-03 11:38 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93254

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
OsteoporosisInt_29_7_1627	pdf	None	1.53 MB	103	2023.12.07

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, K.
	NRID 1000010527708 1000010527708 CreatorName Hirao, M.
	NRID 1000040237938 1000040237938 CreatorName Hashimoto, J.
	CreatorName Matsuoka, H.
	CreatorName Iwahashi, T.
	NRID 1000060803210 1000060803210 CreatorName Chijimatsu, R.
	NRID 1000060898930 1000060898930 CreatorName Etani, Y.
	CreatorName Okamura, G.
	CreatorName Miyama, A.
	NRID 1000060191558 1000060191558 CreatorName Yoshikawa, H.
Subject	Bisphosphonate
	Denosumab
	Joint destruction
	Rheumatoid arthritis
	Teriparatide
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-018-4492-y
Description	Ebina K., Hirao M., Hashimoto J., et al. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis. Osteoporosis International 29, 1627 (2018); https://doi.org/10.1007/s00198-018-4492-y.
Abstract	Summary: In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months. Introduction: The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA). Methods: A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient’s and physician’s wishes, to (1) the BP-continue group (n = 30), (2) the switch-to-DMAb group (n = 30), or (3) the switch-to-TPTD group (n = 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months. Results: After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5; P < 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.3 ± 0.2) than in the BP-continue group (1.0 ± 0.3; P < 0.05) and the switch-to-TPTD group (1.7 ± 0.6; P < 0.05). The logistic regression analysis showed that mTSS changes were significantly associated with the percent changes of TRACP-5b at 6 months (β = 0.30, 95% CI = 0.002–0.016; P < 0.01). Conclusions: Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively.
Publisher	Springer Nature
Source Title	Osteoporosis International
Volume (Issue)	29(7)
Page	1627-1636
Date of Issued	2018-07-01
Language	English
Handle URL	https://hdl.handle.net/11094/93254
PISSN	0937941X
eISSN	14332965
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s00198-018-4492-y
Access Rights	open access
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Osteoporosis International. 2018, 29(7), p. 1627-1636
DC.title	Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis
DC.creator	Ebina, K.
	Hirao, M.
	Hashimoto, J.
	Matsuoka, H.
	Iwahashi, T.
	Chijimatsu, R.
	Etani, Y.
	Okamura, G.
	Miyama, A.
	Yoshikawa, H.
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2018-07-01
DC.identifier	https://doi.org/10.1007/s00198-018-4492-y
DC.subject	Bisphosphonate
	Denosumab
	Joint destruction
	Rheumatoid arthritis
	Teriparatide
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-018-4492-y
DC.description	Ebina K., Hirao M., Hashimoto J., et al. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis. Osteoporosis International 29, 1627 (2018); https://doi.org/10.1007/s00198-018-4492-y.
DCTERMS.abstract	Summary: In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months. Introduction: The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA). Methods: A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient’s and physician’s wishes, to (1) the BP-continue group (n = 30), (2) the switch-to-DMAb group (n = 30), or (3) the switch-to-TPTD group (n = 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months. Results: After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5; P < 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.3 ± 0.2) than in the BP-continue group (1.0 ± 0.3; P < 0.05) and the switch-to-TPTD group (1.7 ± 0.6; P < 0.05). The logistic regression analysis showed that mTSS changes were significantly associated with the percent changes of TRACP-5b at 6 months (β = 0.30, 95% CI = 0.002–0.016; P < 0.01). Conclusions: Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively.
DC.format	93254
citation_title	Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis
citation_author	Ebina, K.
	Hirao, M.
	Hashimoto, J.
	Matsuoka, H.
	Iwahashi, T.
	Chijimatsu, R.
	Etani, Y.
	Okamura, G.
	Miyama, A.
	Yoshikawa, H.
citation_publisher	Springer Nature
citation_language	English
citation_date	2018-07-01
citation_journal_title	Osteoporosis International
citation_volume	29
citation_issue	7
citation_firstpage	1627
citation_lastpage	1636
citation_doi	https://doi.org/10.1007/s00198-018-4492-y
citation_public_url	https://hdl.handle.net/11094/93254

Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis

Link to primary information

Item Information

Show details